Diseases [C] » Infections [C01] » Respiratory Tract Infections
Diseases [C] » Respiratory Tract Diseases [C08] » Respiratory Tract Infections
Description
Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. MeSH
Hierarchy View
Subtype Terms (24)
Bovine Respiratory Disease Complex
Bronchitis
81 drugs (44 approved, 37 experimental)
Common Cold
72 drugs (36 approved, 36 experimental)
Empyema, Pleural
5 approved drugs
Influenza, Human
318 drugs (75 approved, 243 experimental)
Laryngitis
4 drugs (3 approved, 1 experimental)
Lung Abscess
4 approved drugs
Lung Diseases, Fungal
5 drugs (4 approved, 1 experimental)
Pharyngitis
76 drugs (51 approved, 25 experimental)
Pleurisy
3 approved drugs
Pneumonia
253 drugs (160 approved, 93 experimental)
Rhinitis
62 drugs (42 approved, 20 experimental)
Rhinoscleroma
4 approved drugs
Severe Acute Respiratory Syndrome
151 drugs (70 approved, 81 experimental)
Sinusitis
128 drugs (89 approved, 39 experimental)
Tuberculosis, Pleural
1 approved drug
Tuberculosis, Pulmonary
93 drugs (59 approved, 34 experimental)
Whooping Cough
45 drugs (31 approved, 14 experimental)
Approved Indicated Drugs (41)
Phase 4 Indicated Drugs (63)
interferon gamma-1b (actimmune)
live attenuated influenza virus vaccine (Flumist)
Phase 3 Indicated Drugs (59)
Phase 2 Indicated Drugs (37)
Other Experimental Indicated Drugs (24)
Organization Involved with Phase 4 Indications (89)
Adams Respiratory Therapeutics
Associazione Culturale Pediatri
Changchun University of Chinese Medicine
Changzhi City People's Hospital
Changzhou traditional Chinese medicine hospital
China Academy of Chinese Medical Sciences
Chinese University of Hong Kong
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Corporacion Ecuatoriana de Biotecnologia
Guangdong Provincial Hospital of Traditional Chinese Medicine
Guangzhou Yipinhong Pharmaceutical CO.,LTD
Hamilton Health Sciences Corporation
Handan Traditional Chinese Medicine Hospital
Heilongjiang University of Traditional Chinese Medicine
Katholieke Universiteit Leuven
Liaoning Hospital of Traditional Chinese Medicine
Luohe Hospital of Traditional Chinese Medicine
National Health and Medical Research Council, Australia
National Institute of Allergy and Infectious Diseases (NIAID)
Netherlands Organisation for Scientific Research
Norwegian University of Science and Technology
Reckitt Benckiser Pharmaceutical
Shandong University of Traditional Chinese Medicine
South-Eastern Norway Regional Health Authority
Organization Involved with Phase 3 Indications (88)
Ahn-Gook Pharmaceuticals Co.,Ltd
Cantonal Hospital of St. Gallen
Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA
Centers for Disease Control and Prevention (CDC)
Cystic Fibrosis Foundation Therapeutics
Hospital Joan XXIII de Tarragona, Tarragona, Spain
Indian Council of Medical Research
Institute of Hematology and Blood Transfusion, Czech Republic
Institut et Haute école de la Santé, La Source
International Center for Diarrheal Disease Research
Jawaharlal Nehru Medical College
Korea Health Industry Development Institute
Malaria Research and Training Center, Bamako, Mali
Mercy Hospital for Women, Australia
National Cancer Institute (NCI)
National Health Service, United Kingdom
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Child Health, Hungary
Organization Involved with Phase 2 Indications (99)
Aristotle University of Thessaloniki
Assistance Publique - Hôpitaux de Paris
Centre de Recherche St-Louis, Quebec, Canada
Clinical Evaluation Research Unit at Kingston General Hospital
Department of Health, Western Australia
Eastern Virginia Medical School
Fondo Nacional de Investigación y Desarrollo en Salud, Chile
Hellenic Institute for the Study of Sepsis
Hospital Regional de Punta Arenas
Hualan Biological Bacterin Co. Ltd.
Institut National de la Santé Et de la Recherche Médicale, France
Lviv National Medical University
National Institute on Aging (NIA)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institutes of Health (NIH)
Nventa Biopharmaceuticals Corporation
Omnispec Clinical Research Inc, Mirabel, Canada
PathWest Laboratory Medicine WA
Pontificia Universidad Catolica de Chile
The American Geriatrics Society
The Canadian Blood and Marrow Transplant Group
The Physicians' Services Incorporated Foundation
Topstone Research, Toronto, Canada
University of Alabama, Birmingham
University of California, Berkeley
University of California, San Francisco
University of Colorado, Denver
University of North Carolina at Chapel Hill
Organization Involved with Phase 1 Indications (20)
Global Life Technologies Corp.
Health Sciences Centre Foundation, Manitoba
National Autonomous University of Mexico
National Institute of Dental and Craniofacial Research (NIDCR)
Organization Involved with Other Experimental Indications (42)
Hormozgan University of Medical Sciences
Linda and Kenneth Pollin Foundation, Inc.
Liverpool John Moores University
National Center for Complementary and Integrative Health (NCCIH)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
